Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Balovaptan in Healthy Volunteers
NCT03764449Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of balovaptan in Autism Spectrum Disorder (ASD) (2 cohorts), sponsored by Roche. Primary endpoint: Absolute Bioavailability of Oral Balovaptan at Dose Level A and B. Started Jan 2019; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03764449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764449.